Alamar Biosciences, Inc.
NASDAQ:ALMRBiotechnology
+$1.11 today
- Market cap
- $2.12B
- Beta
- 0.00
- P/E (TTM)
- -47.5
- EPS (TTM)
- -$0.45
Volume 0.53M
Average 0.38M
ALMR EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Alamar Biosciences, Inc.NASDAQ: ALMR
EPS (Diluted) · Q2 FY2026 · quarter ended Jun 2026
EPS (Diluted) of -$0.22 in Q2 FY2026
Q2 FY2026 EPS (Diluted) was -$0.22.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 3 analysts of -$1.4 (-211.6%) for the fiscal year ending Dec 2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$0.22+29.0% QoQ
- Last fiscal yearDec 2025
- -$0.45— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | -211.6% | — |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (0.45) USD
- Year-over-year change
- —
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (0.45) | — |
EPS (Diluted) vs competitors
How ALMR compares with its peers on the latest reported figures
- ALMR's FY2025 EPS (Diluted) of -$0.45 is the 4th highest of the 9 companies compared; the peer median is -$0.49.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $1.1 | +124.5% | -13.0% | |
| LTM Mar 2026 | -$0.25 | +28.4% | — | |
| LTM Mar 2026 | -$0.43 | +81.2% | — | |
ALMRAlamar Biosciences, Inc. | FY2025 | -$0.45 | — | — |
| LTM Mar 2026 | -$0.46 | +14.8% | — | |
| LTM Mar 2026 | -$0.51 | +24.4% | — | |
| LTM Sep 2026 | -$0.52 | +16.1% | — | |
| LTM Mar 2026 | -$1.24 | +10.8% | — | |
| LTM Sep 2026 | -$2.08 | -58.8% | — | |
| Peer median (excluding ALMR) | -$0.49 | +20.3% | -13.0% | |
Competitors are the stored peer set for ALMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 74.21M |
| Cost of Revenue | 32.51M |
| Gross Profit | 41.71M |
| Gross Margin | 56.2% |
| Research & Development | 37.47M |
| Selling, General & Admin | 35.57M |
| Operating Expenses | 73.04M |
| Depreciation & Amortization | 3.86M |
| EBITDA | (24.89M) |
| EBITDA Margin | -33.5% |
| Operating Income | (31.33M) |
| Operating Margin | -42.2% |
| Interest Income | 2.16M |
| Interest Expense | 401K |
| Other Income / Expenses | 2.18M |
| Income Before Tax | (29.15M) |
| Pre-Tax Margin | -39.3% |
| Income Tax Expense | 665K |
| Net Income | (29.82M) |
| Net Margin | -40.2% |
| EPS (Basic) | (0.45) |
| EPS (Diluted) | (0.45) |
| Weighted Avg Shares | 66.52M |
| Weighted Avg Shares (Diluted) | 66.52M |
Alamar Biosciences, Inc.
NASDAQ:ALMR
Intrinsic Alpha fair value
Locked
Current Price
$30.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.